Organization | Laureate Institute for Brain Research

Laureate Institute for Brain Research Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3

Founded: Tulsa OK United States (2009)

Organization Overview

First Clinical Trial

2011

NCT01429272

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

Laureate Institute for Brain Research | Laureate Institute for Brain Research, Inc.

Active Ingredients

Drugs in Phase 3 Trials (3)

acetylsalicylic acid (aspirin) (1 trial)

ibuprofen (motrin) (1 trial)

minocycline (minocin) (1 trial)

Drugs in Phase 2 Trials (5)

escitalopram (lexapro) (1 trial)

lipopolysaccharide (2 trials)

rt2ck17 (1 trial)

valaciclovir (Valtrex) (1 trial)

valganciclovir (valcyte) (1 trial)

Drugs in Phase 1 Trials (1)

iti-214 (1 trial)

Drugs in Other Trials (2)

isoprenaline (2 trials)

sodium chloride (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Bipolar Disorder (Phase 3)

Depression (Phase 3)

Depressive Disorder (Phase 3)

Depressive Disorder, Major (Phase 3)

Schizophrenia (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 12
# of Trial APIs: 11